title: Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
abstract: The translocation t(8;21) is one of the most common structural aberrations in acute myeloid leukemia (AML). Excellent response rates and a better relapse-free survival have been described. We analyzed specific morphologic and cytochemical features including dysplasia and other prognostic factors in 41 patients with AML and t(8;21) who underwent aggressive chemotherapy in two national cooperative group studies. Five patients were classified as AML M1 and 36 as AML M2 according to the FAB criteria. Auer rods were detected in 28 patients (68%), however in only 16 patients were they "thin and elongated" as has been described as typical for t(8;21). The presence or absence of Auer rods did not appear to be associated with disease-free survival in this sample. Dysgranulopoiesis was detected in 31/41 patients (90%); five of these patients additionally had dyserythropoiesis (12%). In six cases (15%), dysmegakaryopoiesis was seen in combination with dysgranulopoiesis. Only one patient had trilineage dysplasia. Dysplastic features had no influence on prognosis. Additional cytogenetic abnormalities were detected in 24/41 patients. Twelve male (48%) and four female (25%) had a loss of a sex chromosome. This was correlated with a better disease-free survival (p = 0.039). The complete remission rate (CR) to chemotherapy was 90%. The early death rate was 10%. Disease-free survival of the complete responders was 60% at two years with no relapses observed in ten patients with 2-6 years of follow up. This favorable disease-free survival was observed with a variety of post-induction regimens and t(8;21) had been detected as an independent factor for good prognosis. The need for very intensive therapy, such as bone marrow transplantation, is unanswered at this time.
authors.affiliation: University of Kiel, Second Medical Department, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: J W
authors.initials: JW
authors.lastname: Andersen
authors.forename: N
authors.initials: N
authors.lastname: Tuzuner
authors.forename: P A
authors.initials: PA
authors.lastname: Casslleth
authors.forename: C
authors.initials: C
authors.lastname: Fonatsch
authors.forename: C
authors.initials: C
authors.lastname: Schoch
authors.forename: B
authors.initials: B
authors.lastname: Schlegelberger
authors.forename: R
authors.initials: R
authors.lastname: Becher
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: M C
authors.initials: MC
authors.lastname: Sauerland
authors.forename: A
authors.initials: A
authors.lastname: Heinecke
authors.forename: T
authors.initials: T
authors.lastname: Büchner
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D014178:Translocation, Genetic; D016896:Treatment Outcome